A recent clinical trial reveals that Wegovy, a popular weight-loss drug containing semaglutide, shows promising results in treating liver diseases like MASH. The study, published in the New England Journal of Medicine,

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 or 3 fibrosis.

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results. View on euronews